An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

Affiliations

¹ Department of Medical Oncology, Kasturba Medical College, Manglaore, India.
² Division of Hematology and Oncology, Columbia University Medical Center, New York, New York.
³ Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Hemanth Kumar et al. JAMA Oncol. 2016.

. 2016 Sep 1;2(9):1238-40.

doi: 10.1001/jamaoncol.2016.0931.

¹ Department of Medical Oncology, Kasturba Medical College, Manglaore, India.
² Division of Hematology and Oncology, Columbia University Medical Center, New York, New York.
³ Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

1. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225–1236. - PubMed
1. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539–540. - PubMed
1. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–1280. - PubMed
1. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992–1994. - PubMed